申请人:Astrazeneca AB
公开号:US06667342B1
公开(公告)日:2003-12-23
Compounds of formula (I), pharmaceutically acceptable salts or in vivo hydrolysable esters thereof, wherein: Ring X is phenyl or a six membered heteroaryl ring containing one or two ring nitrogens where said nitrogens are optionally oxidised to form the N-oxide; R1 and R2 are substituents as defined within; R3 and R4 are defined within and are alkyl or halo alkyl or together form a halocycloalkyl ring; R5 is a substituent as defined within; Y—Z is a linking group as defined within; are useful in the production of a elevation of PDH activity in a warm-blooded animal such as a human being. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are described.
公式(I)的化合物、药用可接受的盐或体内可水解的酯,其中:环X是苯基或含有一个或两个环氮的六元杂环芳族环,其中所述氮原子可选择性地被氧化形成N-氧化物;R1和R2是定义内的取代基;R3和R4在定义内定义,是烷基或卤代烷基或共同形成一个卤代环烷基环;R5是定义内的取代基;Y-Z是定义内的连接基团;在制备温血动物如人类体内PDH活性提升方面是有用的。描述了公式(I)化合物的药物组合物、方法和制备过程。